Compare GWAV & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | JAGX |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | GWAV | JAGX |
|---|---|---|
| Price | $6.72 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 91.7K | ★ 336.0K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,144,792.00 | $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.45 |
| 52 Week Low | $4.25 | $1.00 |
| 52 Week High | $90.83 | $33.25 |
| Indicator | GWAV | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 47.11 |
| Support Level | $6.84 | $1.05 |
| Resistance Level | $8.50 | $1.36 |
| Average True Range (ATR) | 0.99 | 0.14 |
| MACD | 0.18 | 0.03 |
| Stochastic Oscillator | 52.90 | 70.00 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio and North Carolina. At these facilities, the company is involved in collecting, classifying, and processing raw scrap metal (ferrous and nonferrous) for recycling. The company involves collecting, classifying and processing appliances, construction material, end-of-life vehicles, boats, and industrial machinery and processing those items by crushing, shearing, shredding, separating, and sorting, into smaller pieces and categorize these recycled ferrous, nonferrous, and mixed metal pieces based on density and metal prior to sale.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.